Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Update

Dyadic International, Inc. (NASDAQ:DYAI) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 121,300 shares, a drop of 22.7% from the December 31st total of 157,000 shares. Based on an average daily trading volume, of 91,200 shares, the short-interest ratio is currently 1.3 days. Currently, 0.6% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Dyadic International in a research note on Thursday, November 14th.

Institutional Investors Weigh In On Dyadic International

Several large investors have recently modified their holdings of DYAI. Truist Financial Corp acquired a new position in Dyadic International during the 4th quarter worth approximately $428,000. Inlet Private Wealth LLC purchased a new stake in shares of Dyadic International in the fourth quarter valued at approximately $52,000. Finally, Chapin Davis Inc. grew its holdings in Dyadic International by 2.5% during the third quarter. Chapin Davis Inc. now owns 868,301 shares of the biotechnology company’s stock worth $903,000 after acquiring an additional 21,000 shares during the period. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Stock Performance

NASDAQ DYAI remained flat at $1.49 on Friday. The company’s stock had a trading volume of 26,454 shares, compared to its average volume of 91,965. The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15. The firm has a market capitalization of $44.09 million, a PE ratio of -6.48 and a beta of 0.89. The company’s 50-day moving average is $1.67 and its 200-day moving average is $1.39. Dyadic International has a one year low of $0.93 and a one year high of $2.67.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. The firm had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same quarter in the prior year, the business earned ($0.06) EPS. On average, sell-side analysts predict that Dyadic International will post -0.18 earnings per share for the current year.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.